Metabolism - Clinical and Experimental
Volume 44, Issue 11 , Pages 1401-1409 , November 1995

Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis

Received 9 July 1994 ,Accepted 6 March 1995.

References 

  1. Gordon T, Castelli WP, Hjortland MC, et al.  High density lipoprotein as a protective factor against coronary heart disease. In: The Framingham Study. ed 3. Am J Med. 62:1977;p. 707–714
  2. Miller NE, Fonde OH, Thelle DS, et al.  The Tromso Heart Study. In: High density lipoprotein and coronary heart disease: A prospective case-control study. ed 3. Lancet. 1:1977;p. 965–967
  3. Goldbourt U, Medalie JH. High density-lipoprotein cholesterol and incidence of coronary heart disease—The Israeli Ischemic Heart Disease Study. Am J Epidemiol. 1979;109:296–308
  4. Vega GL, Grundy SM. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. JAMA. 1989;262:3148–3153
  5. Miller M, Bachorik PS, McCrindle BW, et al.  Effect of gemfibrozil in men with primary isolated low HDL-C: A randomized, double-blind, placebo-controlled, crossover study. Am J Med. 1993;94:7–10
  6. Manninen V, Elo MO, Frick MH. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641–651
  7. Glomset JA. The plasma lecithin cholesterol acetyltransferase reaction. J Lipid Res. 1968;9:155–167
  8. Patsch JB, Karlin JB, Scott LW, et al.  Inverse relationship between blood levels of high density lipoprotein subfraction-2 and magnitude of postprandial lipemia. In: ed 3. Proc Natl Acad Sci USA. 80:1983;p. 1449–1453
  9. Zilversmit DB. Atherogenesis: A postprandial phenomenon. Circulation. 1979;60:473–485
  10. Morganroth J, Levy RI, Fredricksen DS. The biochemical, clinical and genetic features of type III hyperlipoproteinemia. Ann Intern Med. 1975;82:158–164
  11. Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein remnant formation in chronic renal failure. N Engl J Med. 1982;307:327–333
  12. Kane JP, Chen GC, Hamilton RL, et al.  Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia. Arteriosclerosis. 1983;3:47–56
  13. Thompson KH, Zilversmit DB. Plasma very low density lipoprotein (VLDL) in cholesterol-fed rabbits: Chylomicron remnants or liver lipoproteins?. J Nutr. 1983;113:2002–2009
  14. Floren CH, Albers JJ, Bierman EL. Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta. 1981;663:336–349
  15. Eisenberg A. High density lipoprotein metabolism. J Lipid Res. 1984;25:1017–1058
  16. Nikkila EA, Yeikahri R, Huttunen JK. Gemfibrozil effect on serum lipids, lipoproteins, post-heparin plasma lipase activities and glucose tolerance in primary hypertriglyceridemia. In: ed 3. Proc R Soc Med. 69:1976;p. 58–63 (suppl 2)
  17. Saku KS, Gartside PS, Hynd BA, et al.  Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest. 1985;75:1702–1712
  18. Hazzard WR, Bierman EL. Delayed clearance of chylomicron remnants following vitamin A—containing oral fat load in broad-B disease (type III hyperlipoproteinemia). Metabolism. 1976;25:777–801
  19. Wilson DE, Chan I, Ball M. Plasma lipoprotein retinoides after vitamin A feeding in normal man. In: Minimal appearance of retinyl esters among low-density lipoproteins. ed 3. Metabolism. 32:1983;p. 514–517
  20. Berr F, Kern F. Plasma clearance of chylomicrons labelled with retinyl palmitate in healthy human subjects. J Lipid Res. 1984;25:805–812
  21. Wilson DE, Chan I, Buch KN, et al.  Postchallenge plasma lipoprotein retinoids: Chylomicron remnants in endogenous hypertriglyceridemia. Metab Clin Exp. 1985;34:551–558
  22. Berr F, Eckel RH, Kern F. Plasma decay of chylomicron remnants is not affected by heparin-stimulated plasma lipolytic activity in normal fasting man. J Lipid Res. 1985;26:852–859
  23. Cortner JA, Coates PM, Le NA, et al.  Kinetics of chylomicron remnant clearance in normal and hyperlipoproteinemic subjects. J Lipid Res. 1987;28:195–206
  24. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial metabolism in normals and type IIa, type III and type IV hyperlipoproteinemics: Effect of treatment with cholestyramine and gemfibrozil. J Clin Invest. 1987;79:1110–1119
  25. Weintraub MS, Rosen Y, Otto R, et al.  Physical exercise conditioning in the absence of weight loss reduces fasting and postprandial triglyceride-rich lipoprotein levels. Circulation. 1989;79:1007–1014
  26. Weintraub MS, Burstein A, Rassin T, et al.  Severe defect in clearing up postprandial chylomicron remnants in dialysis patients. In: Possible explanations for accelerated atherosclerosis. ed 3. Kidney Int. 47:1989;p. 1247–1252
  27. Rassin I, Liron M, Rubinstein A, et al.  Postprandial lipoprotein clearance in healthy and hypertriglyceridemic subjects. Isr J Med Sci. 1992;28:81–85
  28. Grundy SM, Mok HYI. Chylomicron clearance in normal and hyperlipidemic man. Metabolism. 1976;25:1225–1239
  29. Dale VP, Hamlin JI. Particulate fat in lymph and blood. Physiol Rev. 1962;42:674–701
  30. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In:  Nelson GS editors. Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. New York, NY: Wiley Interscience; 1972;p. 181–274
  31. Blomhoff R, Rasmussen M, Nelsen A, et al.  Hepatic retinal metabolism. J Biol Chem. 1985;260:13560–13565
  32. DeRuyten MGM, Deleenheer AP. Simultaneous determination of retinol and retinyl esters in serum or plasma by reversed-phase high performance liquid chromatography. Clin Chem. 1978;1920–1923
  33. Korn ED. Clearing factor, a heparin activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem. 1955;215:1–14
  34. Blanchette-Mackie EJ, Scow RO. Sites of lipoprotein lipase activity in adipose tissue perfused with chylomicrons. In: Electron microscopic, cytochemical study. ed 3. J Cell Biol. 51:1971;p. 1–25
  35. Schoefe GI, French JE. Vascular permeability to particulate fats: Morphological observation on levels of lactating mammary gland and of lung. In: ed 3. Proc R Soc Biol. 169:1968;p. 153–165
  36. Redgrave TG. Formation of cholesterol-ester—rich particulate lipid during metabolism of chylomicrons. J Clin Invest. 1970;49:465–471
  37. Goodman DS. The metabolism of chylomicron cholesterol ester in the rat. J Clin Invest. 1962;41:1886–1896
  38. Hui DY, Inneranty TL, Makley RW. Lipoprotein binding to canine hepatic membranes: Metabolically distinct apo-E and apo-B,E receptors. J Biol Chem. 1981;256:5646–5655
  39. Mahley RW, Hui DY, Innaranty TL, et al.  Two independent lipoprotein receptors on hepatic membranes of the dog, swine and man. In: The apo-B,E receptors. ed 3. J Clin Invest. 68:1981;p. 1197–1206
  40. Marsh JB. Lipoproteins in a nonrecirculating perfusate of rat liver. J Lipid Res. 1974;15:544–550
  41. Marsh JB. Apoproteins of the lipoproteins in nonrecirculating perfusate of rat liver. J Lipid Res. 1976;17:85–90
  42. Hamilton RL, Williams MC, Fielding CJ, et al.  Discoidal bilayer structure of nascent high density lipoproteins from perfused rat liver. J Clin Invest. 1976;58:667–680
  43. Arab L, Schellenberg B, Schlierf G. Nutrition and health: A survey of young men and women in Heidelberg. Ann Nutr Metab. 1982;26(suppl 1):1–244
  44. Nestel PJ, Billington T, Smith B. Low density and high density lipoprotein kinetics and sterol balance in vegetarians. Metabolism. 1981;30:941–945
  45. McGill H, McMahan CA, Wene JD. Unresolved problems in the diet-heart issue. Arteriosclerosis. 1981;1:164–176
  46. Oster P, Schlierf G, Henck CC, et al.  Diet and high density lipoproteins. Lipids. 1981;26:93–97
  47. Schlierf G, Arab L, Oster P. Influence of diet on high density lipoproteins. Am J Cardiol. 1983;52:17B–19B

PII: 0026-0495(95)90137-X

Metabolism - Clinical and Experimental
Volume 44, Issue 11 , Pages 1401-1409 , November 1995

Article Tools